You can buy Luciquiza at the lowest price from Nextgen.ooo online pharmacy. Quizartinib is an orally available fms-like tyrosine kinase 3 (FLT3) inhibitor and is the first drug designed specifically to target FLT3, as other agents with FLT3 inhibitory activity have been studied with other targets in mind. In addition, quizartinib also exhibits inhibitory activity against internal tandem duplication (ITD) FLT3, albeit with 10-fold lower affinity compared to wild-type FLT3. FLT3-ITD mutation is present in 75% of FLT3-mutated AML, resulting in constitutively active FLT3 and thus poorer overall survival and higher risk of relapse. Multiple clinical trials have demonstrated the efficacy of quizartinib in relapsed/refractory FLT3-ITD-mutated AML. Thus, quizartinib has been shown to be a useful addition to the current AML treatment regimen, although serious adverse events such as QT prolongation require further studies to optimize the addition of quizartinib to the standard of care for AML.
 
Quizartinib was approved by the FDA in July 2023. The FDA approval was based on positive results from the QuANTUM-First trial in FLT3-ITD-positive AML, where quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation followed by maintenance monotherapy resulted in a 22% reduction in the risk of death.